Table 1 Data analysis 1ST order concept...

Table 1

Data analysis

1ST order concept	2ND-order themes	Aggregate dimensions
Alira Health
“The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT's global biometrics capabilities will enhance Alira Health's unique ability to serve clients across their solutions lifecycle.”	Clinical evidence base	Effective null convergence
“CROS NT is delighted to join Alira Health to better serve our clients by providing a complete portfolio of services and solutions. We are excited to contribute to Alira Health's mission of healthcare transformation, creating value for patients. Our experienced team of professionals will deliver value through our combined services, accelerating innovation and delivering tomorrow's standard of care to patients.”	Clinical evidence base
“We are privileged to collaborate with the Patient Empowerment Network. Together, we empower patients to take charge of their healthcare experiences through the utilization of meaningful data that patients own and have control over […] In today's context, prioritizing patients and granting them and their support networks the capacity to chart their healthcare paths is of utmost importance. We firmly believe that well-informed, respected, and engaged patients are more likely to make informed decisions, leading to improved health outcomes. As patients gain access to this growing resource of healthcare and treatment information, they become better equipped to be advocates for their own well-being […] We are excited to establish this partnership with Alira Health and the Health Storylines app,” said Tracy Rode, Executive Director at the Patient Empowerment Network […] We are confident that this will provide our community of patients and caregivers with an additional resource to effectively oversee their well-being and flourish.”	Personalized care gains
“If you are medically diagnosed with a schizophrenia or a related brain disorder, my wish is you find the same hope I did by simply using this priceless app.”
“At Alira Health we invest a lot of time in building our family around very core values. We believe in: being inclusive … being courageous … being honest … being accountable … [and] elevating others”
“This is a fantastic application … It gives you the opportunity to track not only medication use, but also daily moods and habits […] you are able to see patterns over time.”
“Gustave Roussy is leading a transformational shift in cancer prevention, and we are honored to support them with SpherePX […] Our technology bridges the gap between research and real-world care, ensuring that high-risk individuals receive the personalized prevention plans they need. By integrating digital health solutions with real-world evidence, we can drive earlier interventions and improve long-term outcomes.”	Clinical data for AI	Effective symmetric convergence
“The innovative part of our approach is how we engage with patients. The Alira Health difference is we do not recruit patients for only a particular Clinical and RWE study. We already have patients active on our platforms using our technology to manage their conditions, and we empower them with education on what it means to be part of a study and partner with them all along. We now have over 160,000 patients on our technology platforms.”
“SpherePX's Proven Market Expertise: – 60+ Clinical Studies, – 150K+ Patients Engaged, – 50+ Therapeutic Areas, – 20+ Countries, – 15+ Languages”
“SpherePX's Monitoring Capabilities: reduce administrative burden (automate documentation and workflows so teams can focus on care); streamline patient management (automate documentation and workflows so teams can focus on care); access real-time data (monitor study performance and patient input as its captured)”	Monitoring improves outcomes
“I use it (Health Storylines app) everyday to keeping track of vitals and taking my medication. I love the fact that you can journal your feelings and reflect on emotions and what got you to where you are now. You can even input your moods and keep track of your upcoming appointments. […] I definitely would recommend”
“This app has so many ways to track your lifestyle and see not only what your triggers are and how often they show up. It's a great app and I would recommend it to anyone.”
“This is a great app for me since I like tracking my health when I get sick. It's a lot easier to make conclusions when you have analytics.”	Data-driven delivery	Effective asymmetric convergence
“The integration has been profound. Our financial, staffing, and travel management systems now speak the same language, thanks to Workday […] We see Workday as a partner in our growth, not just as a platform. It's about enhancing our data quality and capabilities to support strategic analysis and decision-making,”	Data-driven delivery
“Patient stories are powerful advocacy tools. We are now in the age that enables us to use advanced technology to unfold these stories – as a result, the newest patient-reported, evidence-based tools allow patient advocacy groups to capture analytics and insights into the journey of each patient and leverage these data points to deliver better care, helping patients, their families, and care teams.”	Clinical data for AI
“AI solutions are designed to allow real-time information, enabling practitioners to focus on a much smaller pool of patients and obtain a clear and complete dataset. In addition, the data collection and analysis present that a clearer image of patient information allows a greater focus on personalized care and the real needs of individuals”	Clinical data for AI
“We are extremely pleased to acquire CROS NT's Biometrics services globally. The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT's global biometrics capabilities will enhance Alira Health's unique ability to serve clients across their solutions lifecycle. The addition of CROS NT will also enable Alira Health to expand our direct clinical operations in Europe. We embrace CROS NT's commitment and passion to being a visionary in clinical research and are proud to welcome CROS NT CEO, Paolo Morelli, and his team to our fast-growing company.”	Tech scaling friction	Dysfunctional null convergence
“Project Interception is being implemented at six medical centers, with approximately 490 patients enrolled and 85 healthcare professionals engaged. The long-term goal is to expand the program to 30 sites across France, ultimately reaching 2,000 patients per site each year. As the initiative grows, Gustave Roussy and Alira Health invite healthcare institutions, policymakers, and patient advocacy groups to collaborate in advancing global cancer prevention efforts.”	Tech scaling friction
“The Medication Tracker, Symptom Tracker, and Vitals are not working for me, but everything else is absolutely wonderful! […] This app treats the whole patient, mind, body, and soul – not just the physical aspects of your illness.”	Delivery instability
“We had to think globally and act swiftly to address our growing pains. We were tasked with unifying a workforce that was rapidly scaling across various countries and cultures.”	Delivery instability
Pieces Clinical Solutions
“Digital platforms ensure the interaction of patients with medical institutions and provides support to medical staff in the course of accompanying the patient.”	AI workflow support	Effective symmetric convergence
“I've been with Picis as a client for several hospitals in the past 18 years and always had great experience with the performance of their solutions.”
“Picis was the only vendor that could deliver on all our objectives and provide the necessary integration with our other hospital information systems.”
“None of my colleagues would want to return to a paper record because we now realize the many benefits of computerized anesthesia charting.”
“Picis is the core system that provides near real-time data to help clinicians make informed decisions.”
“The drug delivery systems (DDS) market is undergoing a structural transformation, driven by the rapid expansion of biologics, intensified competition in GLP-1s and biosimilars, and the growing demand for patient-centric and sustainable solutions. Devices are no longer viewed simply as delivery tools; they are becoming platforms for differentiation, real-world evidence generation, and healthcare system efficiency. […] DDS providers are embedding digital features and co-developing devices with patients to improve adherence tracking, generate real-world evidence, and enhance usability in diabetes, GLP-1 therapies, and rare chronic diseases. Sustainability is becoming a critical priority, with reusable injectors, eco-packaging, and greener manufacturing aligned with PPWR 2035 and ESG commitments now essential in pharmaceutical partnerships and procurement decisions.”	Clinical-digital modules
“AI mechanisms allow healthcare facilities to develop new and digital solutions that simplify the complex healthcare value chain and adapt to the digitization phenomenon.”
“The global biosimilar market has matured significantly in recent years, with the US and EU leading this expansion […] Regulatory advances, such as the IRA and updated FDA guidance on biosimilar interchangeability, are driving this growth. With patent expirations and increasing biosimilar approvals, the market is on track to surpass $64 billion by 2028. This represents a significant shift in healthcare, delivering the benefits of biologics at reduced costs and expanding patient access while alleviating financial pressures on health systems.”
“Biopharma companies partner with contract development and manufacturing organizations (CDMOs) to receive end-to-end drug-device continuum support that enhances efficiency, scalability, and speed to market. CDMOs are investing heavily to expand capabilities upstream in design, automation, digital manufacturing, and downstream in drug product development and fill-finish.”
“We are bringing to market a new model of solutions and services that are promoting the democratization of life sciences research.”
“AI Assistant Feature Suite for Patients and Clinicians: Conversational Study Support (give users instant answers about the study through a conversational chat interface with an AI assistant trained on your protocol); AI-enhanced questionnaires (attach an AI assistant that listens to dictation, transcribes the output, interprets the meaning using your AI model, and maps the output directly to structured eCRF fields; Automated data extraction (pre-populate forms with data extracted from medical records)”	Platform automation readiness	Effective asymmetric convergence
“AI is used to enhance internal processes related to both product realization and service provision.”
“AI solutions allow start-up entrepreneurs and companies to get feedback from medical peers before proceeding with the commercialization of products. A large audience coverage allows users to convey the idea to potential investors, and partners, assess potential demand, and so on. An important feature of the platform is the combination of private and public funding opportunities that have gone through the securities review process.”
“Prevention and Care Management Activities: Patient Support Programs that ensure patient engagement and adherence as well as health care professional coordination throughout the care pathway; Patient Remote Monitoring that reinvents the link between the patient and healthcare professionals with our state-of-the art prevention and monitoring technologies; Primary Prevention at Work offers value-added services to your employees with health risk screening solutions in the workplace; Risk Screening Campaigns like cardio-metabolic risk screening campaigns with certified nurses within companies, public places, thanks to our state-of the art digital solution and connected devices”	Monitoring improves outcomes
“AI integration enables healthcare systems to create value for patients and the different actors involved by achieving a suitable trade-off between high-quality care and cost containment.”	Monitoring improves outcomes
“Technology alone won't enroll patients in clinical studies; it's an enabler which you can combine with clinical expertise and patient engagement to succeed in recruitment. You need deep knowledge and experience to make technology beneficial, and you must include the human component. I've seen companies fail when they relied totally on technology and left out the human interaction, especially when it comes to not just finding patients but convincing them to participate. For example, we were running a study in an older population living with diabetes, and because digital technology was the only option for participation, these patients felt they couldn't be a part of the study because they didn't have smartphones.”	Digital exclusion risk	Dysfunctional asymmetric convergence
“Digital advertising allows us to reach out to potential targets for study participation. We use display ads to mobilize patients to a landing page where we explain the benefit of the study and the type of person who would be perfect for this study. People register themselves as a potential participant and then we share more information with them. This technology allows us to cast a wide net for finding patients, while also enabling a seamless experience in the background to capture patient information, connect patients with the PI, and communicate with them going forward. This is, of course, combined with off-line techniques, such as engaging with patient associations.”	Digital exclusion risk
“Another issue is that the sponsor often considers enrollment the responsibility of the principal investigator (PI) and the study team at the hospital. This situation results in frustration on all sides. The study team doesn't have the time or bandwidth because they're running multiple studies and have numerous responsibilities. Don't expect the study team to solve recruitment for you. Certainly, one of your strategies can be to talk to the investigator, but you need to find a way to support them and work collaboratively.”	Trial execution delays
“Through constant optimization and a rigorous human-in-the-loop review process, Pieces reaches low summary error rates. Their AI agents allow personalization down to the individual doctor level.”	Trial execution delays
Kelyon
“high quality and in-depth data are necessary for current analyses but difficult to obtain,”	Clinical-tech misfit	Dysfunctional symmetric convergence
“Digital solution brings together stakeholders such as healthcare providers, clinical evaluators, and payers, thus affecting the speed and quality of medical services.”	Clinical-tech misfit
“I would like a simpler app.”	Trust adoption friction
“A more formal chatbot.”	Trust adoption friction
“I also see a challenge in patients' willingness to participate in a clinical study. Patients are reluctant to participate for various reasons, including their physical abilities, lack of transportation, and the time commitment, including time away from work (which can affect income) or family. Sometimes patients don't trust the clinical study process and have concerns about receiving a drug that's not approved or a device that's not cleared. These very human issues can further limit your patient population.”	Clinical input constraints	Dysfunctional asymmetric convergence
“Sometimes limited budgets and lack of knowledge of other options, can make them think they should stick to traditional approaches, such as relying on the PI, but what's been done for years doesn't necessarily work anymore. And PIs are concentrating on the investigation and they simply cannot handle everything. So I think that sponsors should think a little bit outside of the box, and consider strategies that may take them beyond their comfort zone.”	Clinical input constraints
“Another major challenge related to that is that studies are seldom co-designed with patients. During the co-design process, patients can provide input as to what will work and what won't, identifying logistical problems in the proposed study protocol and letting you know what's truly feasible. For example, you can ask patients if the number of times they would be expected to visit the hospital is possible, rather than assuming that it will be. If sponsors involve patients in study planning early on, they can significantly improve patient recruitment.”	Co-design gaps
“We are a global company with the mission to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. We feel accountable at every turn of the biopharma and medical technology development cycle. We are bringing to market a new model of solutions and services promoting the democratization of life sciences research”	Co-design gaps
“You need deep knowledge and experience to make technology beneficial, and you must include the human component. I've seen companies fail when they relied totally on technology and left out the human interaction, especially when it comes to not just finding patients but convincing them to participate. For example, we were running a study in an older population living with diabetes, and because digital technology was the only option for participation, these patients felt they couldn't be a part of the study because they didn't have smartphones.”	Digital exclusion risk	Ambivalent symmetric convergence
“Through a tele-monitoring and online training model, Moira contributes to improving the quality of life of patients and their care givers by facilitating development of care pathways tailored to the unique needs of each patient and family.”	Digital exclusion risk
“Implementing digital solutions, such as Artificial Intelligence mechanisms helps developing innovative products or new ways of delivering care.”	Clinical-digital modules
“The objective of Project Interception is to reduce the risk of stage 2 or higher (or equivalent) malignant tumors by 30% over five years by identifying individuals at increased risk of cancer as early as possible and offering them a personalized course of screening and prevention. Research shows that up to 40% of cancer cases are preventable, yet traditional screening methods often fail to address individual risk factors. Project Interception shifts the focus from late-stage diagnosis to proactive, personalized prevention and monitoring, leveraging digital health solutions to enhance both patient engagement and clinical decision-making.”	Clinical-digital modules
“AI mechanisms are designed for long-term participation in complex clinical trials and offers a virtual assistant for study participants to increase engagement. The patented design of the solution motivates study participants to continue procedures and adapts to the needs of the individual participant. The company's clients receive prevention drop-out and maximize compliance with proprietary engagement strategies that autonomously promote adherence.”	AI workflow support	Ambivalent asymmetric convergence
“An AI Assistant Feature Suite for Study Administrators: Build Custom AI Assistants (quickly create AI assistants using tailored prompts and uploaded study documents); Targeted AI deployment (decide exactly where and how each assistant functions. Attach a specific assistant to an individual question, entire questionnaire, or place an informational chatbot on the study landing page); Smart Access to Study Insights enable real-time answers to queries about your study or participants pulled from pre-defined fields in your study database or connected systems.”	AI workflow support
“Operationally, I have seen that a sponsor or CRO often selects one strategy to boost recruitment, and then waits to see if that strategy will work. The problem with that is, six months will pass and if that strategy wasn't successful, they've delayed their timeline, wasted money, and have not solved the problem. In fact, you probably have to execute on 20 different strategies simultaneously, and continuously assess them and re-evaluate if needed.”	Trial execution delays
“Build in defined time points and risk mitigation right from the beginning of the project, and anticipate recruitment issues because no matter what, it's not going to be easy. You can't just set a target metric and then come back six months, twelve months, even 24 months later to find that you are way behind.” […] “These delays can result in having to resubmit protocols, which costs still more time and money. It's not just that you're losing the opportunity for recruitment; the consequences to your company can be enormous.”	Trial execution delays
“We adopted a minimal viable product approach, which allowed us to leverage the core functionalities quickly and lay the groundwork for future enhancements,”	Platform automation readiness	Ambivalent null convergence
“Flora is an innovative modular platform designed to optimize collaboration among healthcare professionals, facilitate workflow management, and improve efficiency in multicenter settings. Thanks to secure and rapid sharing of clinical data, Flora enables physicians, specialists, and supervisors to coordinate effectively, ensuring an unprecedented continuity of care.”	Platform automation readiness
“The chatbot and the app sometimes freeze or won't let me continue.”	Delivery instability
“Integrating new digital tools into existing information systems requires investment, training, and a cultural shift among healthcare professionals – processes that are not immediately feasible.”	Delivery instability

1ST order concept	2ND-order themes	Aggregate dimensions
Alira Health
“The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT's global biometrics capabilities will enhance Alira Health's unique ability to serve clients across their solutions lifecycle.”	Clinical evidence base	Effective null convergence
“CROS NT is delighted to join Alira Health to better serve our clients by providing a complete portfolio of services and solutions. We are excited to contribute to Alira Health's mission of healthcare transformation, creating value for patients. Our experienced team of professionals will deliver value through our combined services, accelerating innovation and delivering tomorrow's standard of care to patients.”	Clinical evidence base
“We are privileged to collaborate with the Patient Empowerment Network. Together, we empower patients to take charge of their healthcare experiences through the utilization of meaningful data that patients own and have control over […] In today's context, prioritizing patients and granting them and their support networks the capacity to chart their healthcare paths is of utmost importance. We firmly believe that well-informed, respected, and engaged patients are more likely to make informed decisions, leading to improved health outcomes. As patients gain access to this growing resource of healthcare and treatment information, they become better equipped to be advocates for their own well-being […] We are excited to establish this partnership with Alira Health and the Health Storylines app,” said Tracy Rode, Executive Director at the Patient Empowerment Network […] We are confident that this will provide our community of patients and caregivers with an additional resource to effectively oversee their well-being and flourish.”	Personalized care gains
“If you are medically diagnosed with a schizophrenia or a related brain disorder, my wish is you find the same hope I did by simply using this priceless app.”
“At Alira Health we invest a lot of time in building our family around very core values. We believe in: being inclusive … being courageous … being honest … being accountable … [and] elevating others”
“This is a fantastic application … It gives you the opportunity to track not only medication use, but also daily moods and habits […] you are able to see patterns over time.”
“Gustave Roussy is leading a transformational shift in cancer prevention, and we are honored to support them with SpherePX […] Our technology bridges the gap between research and real-world care, ensuring that high-risk individuals receive the personalized prevention plans they need. By integrating digital health solutions with real-world evidence, we can drive earlier interventions and improve long-term outcomes.”	Clinical data for AI	Effective symmetric convergence
“The innovative part of our approach is how we engage with patients. The Alira Health difference is we do not recruit patients for only a particular Clinical and RWE study. We already have patients active on our platforms using our technology to manage their conditions, and we empower them with education on what it means to be part of a study and partner with them all along. We now have over 160,000 patients on our technology platforms.”
“SpherePX's Proven Market Expertise: – 60+ Clinical Studies, – 150K+ Patients Engaged, – 50+ Therapeutic Areas, – 20+ Countries, – 15+ Languages”
“SpherePX's Monitoring Capabilities: reduce administrative burden (automate documentation and workflows so teams can focus on care); streamline patient management (automate documentation and workflows so teams can focus on care); access real-time data (monitor study performance and patient input as its captured)”	Monitoring improves outcomes
“I use it (Health Storylines app) everyday to keeping track of vitals and taking my medication. I love the fact that you can journal your feelings and reflect on emotions and what got you to where you are now. You can even input your moods and keep track of your upcoming appointments. […] I definitely would recommend”
“This app has so many ways to track your lifestyle and see not only what your triggers are and how often they show up. It's a great app and I would recommend it to anyone.”
“This is a great app for me since I like tracking my health when I get sick. It's a lot easier to make conclusions when you have analytics.”	Data-driven delivery	Effective asymmetric convergence
“The integration has been profound. Our financial, staffing, and travel management systems now speak the same language, thanks to Workday […] We see Workday as a partner in our growth, not just as a platform. It's about enhancing our data quality and capabilities to support strategic analysis and decision-making,”	Data-driven delivery
“Patient stories are powerful advocacy tools. We are now in the age that enables us to use advanced technology to unfold these stories – as a result, the newest patient-reported, evidence-based tools allow patient advocacy groups to capture analytics and insights into the journey of each patient and leverage these data points to deliver better care, helping patients, their families, and care teams.”	Clinical data for AI
“AI solutions are designed to allow real-time information, enabling practitioners to focus on a much smaller pool of patients and obtain a clear and complete dataset. In addition, the data collection and analysis present that a clearer image of patient information allows a greater focus on personalized care and the real needs of individuals”	Clinical data for AI
“We are extremely pleased to acquire CROS NT's Biometrics services globally. The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT's global biometrics capabilities will enhance Alira Health's unique ability to serve clients across their solutions lifecycle. The addition of CROS NT will also enable Alira Health to expand our direct clinical operations in Europe. We embrace CROS NT's commitment and passion to being a visionary in clinical research and are proud to welcome CROS NT CEO, Paolo Morelli, and his team to our fast-growing company.”	Tech scaling friction	Dysfunctional null convergence
“Project Interception is being implemented at six medical centers, with approximately 490 patients enrolled and 85 healthcare professionals engaged. The long-term goal is to expand the program to 30 sites across France, ultimately reaching 2,000 patients per site each year. As the initiative grows, Gustave Roussy and Alira Health invite healthcare institutions, policymakers, and patient advocacy groups to collaborate in advancing global cancer prevention efforts.”	Tech scaling friction
“The Medication Tracker, Symptom Tracker, and Vitals are not working for me, but everything else is absolutely wonderful! […] This app treats the whole patient, mind, body, and soul – not just the physical aspects of your illness.”	Delivery instability
“We had to think globally and act swiftly to address our growing pains. We were tasked with unifying a workforce that was rapidly scaling across various countries and cultures.”	Delivery instability
Pieces Clinical Solutions
“Digital platforms ensure the interaction of patients with medical institutions and provides support to medical staff in the course of accompanying the patient.”	AI workflow support	Effective symmetric convergence
“I've been with Picis as a client for several hospitals in the past 18 years and always had great experience with the performance of their solutions.”
“Picis was the only vendor that could deliver on all our objectives and provide the necessary integration with our other hospital information systems.”
“None of my colleagues would want to return to a paper record because we now realize the many benefits of computerized anesthesia charting.”
“Picis is the core system that provides near real-time data to help clinicians make informed decisions.”
“The drug delivery systems (DDS) market is undergoing a structural transformation, driven by the rapid expansion of biologics, intensified competition in GLP-1s and biosimilars, and the growing demand for patient-centric and sustainable solutions. Devices are no longer viewed simply as delivery tools; they are becoming platforms for differentiation, real-world evidence generation, and healthcare system efficiency. […] DDS providers are embedding digital features and co-developing devices with patients to improve adherence tracking, generate real-world evidence, and enhance usability in diabetes, GLP-1 therapies, and rare chronic diseases. Sustainability is becoming a critical priority, with reusable injectors, eco-packaging, and greener manufacturing aligned with PPWR 2035 and ESG commitments now essential in pharmaceutical partnerships and procurement decisions.”	Clinical-digital modules
“AI mechanisms allow healthcare facilities to develop new and digital solutions that simplify the complex healthcare value chain and adapt to the digitization phenomenon.”
“The global biosimilar market has matured significantly in recent years, with the US and EU leading this expansion […] Regulatory advances, such as the IRA and updated FDA guidance on biosimilar interchangeability, are driving this growth. With patent expirations and increasing biosimilar approvals, the market is on track to surpass $64 billion by 2028. This represents a significant shift in healthcare, delivering the benefits of biologics at reduced costs and expanding patient access while alleviating financial pressures on health systems.”
“Biopharma companies partner with contract development and manufacturing organizations (CDMOs) to receive end-to-end drug-device continuum support that enhances efficiency, scalability, and speed to market. CDMOs are investing heavily to expand capabilities upstream in design, automation, digital manufacturing, and downstream in drug product development and fill-finish.”
“We are bringing to market a new model of solutions and services that are promoting the democratization of life sciences research.”
“AI Assistant Feature Suite for Patients and Clinicians: Conversational Study Support (give users instant answers about the study through a conversational chat interface with an AI assistant trained on your protocol); AI-enhanced questionnaires (attach an AI assistant that listens to dictation, transcribes the output, interprets the meaning using your AI model, and maps the output directly to structured eCRF fields; Automated data extraction (pre-populate forms with data extracted from medical records)”	Platform automation readiness	Effective asymmetric convergence
“AI is used to enhance internal processes related to both product realization and service provision.”
“AI solutions allow start-up entrepreneurs and companies to get feedback from medical peers before proceeding with the commercialization of products. A large audience coverage allows users to convey the idea to potential investors, and partners, assess potential demand, and so on. An important feature of the platform is the combination of private and public funding opportunities that have gone through the securities review process.”
“Prevention and Care Management Activities: Patient Support Programs that ensure patient engagement and adherence as well as health care professional coordination throughout the care pathway; Patient Remote Monitoring that reinvents the link between the patient and healthcare professionals with our state-of-the art prevention and monitoring technologies; Primary Prevention at Work offers value-added services to your employees with health risk screening solutions in the workplace; Risk Screening Campaigns like cardio-metabolic risk screening campaigns with certified nurses within companies, public places, thanks to our state-of the art digital solution and connected devices”	Monitoring improves outcomes
“AI integration enables healthcare systems to create value for patients and the different actors involved by achieving a suitable trade-off between high-quality care and cost containment.”	Monitoring improves outcomes
“Technology alone won't enroll patients in clinical studies; it's an enabler which you can combine with clinical expertise and patient engagement to succeed in recruitment. You need deep knowledge and experience to make technology beneficial, and you must include the human component. I've seen companies fail when they relied totally on technology and left out the human interaction, especially when it comes to not just finding patients but convincing them to participate. For example, we were running a study in an older population living with diabetes, and because digital technology was the only option for participation, these patients felt they couldn't be a part of the study because they didn't have smartphones.”	Digital exclusion risk	Dysfunctional asymmetric convergence
“Digital advertising allows us to reach out to potential targets for study participation. We use display ads to mobilize patients to a landing page where we explain the benefit of the study and the type of person who would be perfect for this study. People register themselves as a potential participant and then we share more information with them. This technology allows us to cast a wide net for finding patients, while also enabling a seamless experience in the background to capture patient information, connect patients with the PI, and communicate with them going forward. This is, of course, combined with off-line techniques, such as engaging with patient associations.”	Digital exclusion risk
“Another issue is that the sponsor often considers enrollment the responsibility of the principal investigator (PI) and the study team at the hospital. This situation results in frustration on all sides. The study team doesn't have the time or bandwidth because they're running multiple studies and have numerous responsibilities. Don't expect the study team to solve recruitment for you. Certainly, one of your strategies can be to talk to the investigator, but you need to find a way to support them and work collaboratively.”	Trial execution delays
“Through constant optimization and a rigorous human-in-the-loop review process, Pieces reaches low summary error rates. Their AI agents allow personalization down to the individual doctor level.”	Trial execution delays
Kelyon
“high quality and in-depth data are necessary for current analyses but difficult to obtain,”	Clinical-tech misfit	Dysfunctional symmetric convergence
“Digital solution brings together stakeholders such as healthcare providers, clinical evaluators, and payers, thus affecting the speed and quality of medical services.”	Clinical-tech misfit
“I would like a simpler app.”	Trust adoption friction
“A more formal chatbot.”	Trust adoption friction
“I also see a challenge in patients' willingness to participate in a clinical study. Patients are reluctant to participate for various reasons, including their physical abilities, lack of transportation, and the time commitment, including time away from work (which can affect income) or family. Sometimes patients don't trust the clinical study process and have concerns about receiving a drug that's not approved or a device that's not cleared. These very human issues can further limit your patient population.”	Clinical input constraints	Dysfunctional asymmetric convergence
“Sometimes limited budgets and lack of knowledge of other options, can make them think they should stick to traditional approaches, such as relying on the PI, but what's been done for years doesn't necessarily work anymore. And PIs are concentrating on the investigation and they simply cannot handle everything. So I think that sponsors should think a little bit outside of the box, and consider strategies that may take them beyond their comfort zone.”	Clinical input constraints
“Another major challenge related to that is that studies are seldom co-designed with patients. During the co-design process, patients can provide input as to what will work and what won't, identifying logistical problems in the proposed study protocol and letting you know what's truly feasible. For example, you can ask patients if the number of times they would be expected to visit the hospital is possible, rather than assuming that it will be. If sponsors involve patients in study planning early on, they can significantly improve patient recruitment.”	Co-design gaps
“We are a global company with the mission to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. We feel accountable at every turn of the biopharma and medical technology development cycle. We are bringing to market a new model of solutions and services promoting the democratization of life sciences research”	Co-design gaps
“You need deep knowledge and experience to make technology beneficial, and you must include the human component. I've seen companies fail when they relied totally on technology and left out the human interaction, especially when it comes to not just finding patients but convincing them to participate. For example, we were running a study in an older population living with diabetes, and because digital technology was the only option for participation, these patients felt they couldn't be a part of the study because they didn't have smartphones.”	Digital exclusion risk	Ambivalent symmetric convergence
“Through a tele-monitoring and online training model, Moira contributes to improving the quality of life of patients and their care givers by facilitating development of care pathways tailored to the unique needs of each patient and family.”	Digital exclusion risk
“Implementing digital solutions, such as Artificial Intelligence mechanisms helps developing innovative products or new ways of delivering care.”	Clinical-digital modules
“The objective of Project Interception is to reduce the risk of stage 2 or higher (or equivalent) malignant tumors by 30% over five years by identifying individuals at increased risk of cancer as early as possible and offering them a personalized course of screening and prevention. Research shows that up to 40% of cancer cases are preventable, yet traditional screening methods often fail to address individual risk factors. Project Interception shifts the focus from late-stage diagnosis to proactive, personalized prevention and monitoring, leveraging digital health solutions to enhance both patient engagement and clinical decision-making.”	Clinical-digital modules
“AI mechanisms are designed for long-term participation in complex clinical trials and offers a virtual assistant for study participants to increase engagement. The patented design of the solution motivates study participants to continue procedures and adapts to the needs of the individual participant. The company's clients receive prevention drop-out and maximize compliance with proprietary engagement strategies that autonomously promote adherence.”	AI workflow support	Ambivalent asymmetric convergence
“An AI Assistant Feature Suite for Study Administrators: Build Custom AI Assistants (quickly create AI assistants using tailored prompts and uploaded study documents); Targeted AI deployment (decide exactly where and how each assistant functions. Attach a specific assistant to an individual question, entire questionnaire, or place an informational chatbot on the study landing page); Smart Access to Study Insights enable real-time answers to queries about your study or participants pulled from pre-defined fields in your study database or connected systems.”	AI workflow support
“Operationally, I have seen that a sponsor or CRO often selects one strategy to boost recruitment, and then waits to see if that strategy will work. The problem with that is, six months will pass and if that strategy wasn't successful, they've delayed their timeline, wasted money, and have not solved the problem. In fact, you probably have to execute on 20 different strategies simultaneously, and continuously assess them and re-evaluate if needed.”	Trial execution delays
“Build in defined time points and risk mitigation right from the beginning of the project, and anticipate recruitment issues because no matter what, it's not going to be easy. You can't just set a target metric and then come back six months, twelve months, even 24 months later to find that you are way behind.” […] “These delays can result in having to resubmit protocols, which costs still more time and money. It's not just that you're losing the opportunity for recruitment; the consequences to your company can be enormous.”	Trial execution delays
“We adopted a minimal viable product approach, which allowed us to leverage the core functionalities quickly and lay the groundwork for future enhancements,”	Platform automation readiness	Ambivalent null convergence
“Flora is an innovative modular platform designed to optimize collaboration among healthcare professionals, facilitate workflow management, and improve efficiency in multicenter settings. Thanks to secure and rapid sharing of clinical data, Flora enables physicians, specialists, and supervisors to coordinate effectively, ensuring an unprecedented continuity of care.”	Platform automation readiness
“The chatbot and the app sometimes freeze or won't let me continue.”	Delivery instability
“Integrating new digital tools into existing information systems requires investment, training, and a cultural shift among healthcare professionals – processes that are not immediately feasible.”	Delivery instability

[ViewLarge]

Sharing Unavailable